405 related articles for article (PubMed ID: 18443215)
1. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Rollison DE; Howlader N; Smith MT; Strom SS; Merritt WD; Ries LA; Edwards BK; List AF
Blood; 2008 Jul; 112(1):45-52. PubMed ID: 18443215
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndromes: incidence and survival in the United States.
Ma X; Does M; Raza A; Mayne ST
Cancer; 2007 Apr; 109(8):1536-42. PubMed ID: 17345612
[TBL] [Abstract][Full Text] [Related]
3. Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries.
Benzarti S; Daskalakis M; Feller A; Bacher VU; Schnegg-Kaufmann A; Rüfer A; Holbro A; Schmidt A; Benz R; Solenthaler M; Stussi G; Arndt V; Bonadies N;
Cancer Epidemiol; 2019 Apr; 59():51-57. PubMed ID: 30690330
[TBL] [Abstract][Full Text] [Related]
4. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.
Cogle CR; Craig BM; Rollison DE; List AF
Blood; 2011 Jun; 117(26):7121-5. PubMed ID: 21531980
[TBL] [Abstract][Full Text] [Related]
5. Underreporting of myeloid malignancies by United States cancer registries.
Craig BM; Rollison DE; List AF; Cogle CR
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):474-81. PubMed ID: 22237987
[TBL] [Abstract][Full Text] [Related]
6. Incidence, survival and prevalence of myeloid malignancies in Europe.
Visser O; Trama A; Maynadié M; Stiller C; Marcos-Gragera R; De Angelis R; Mallone S; Tereanu C; Allemani C; Ricardi U; Schouten HC;
Eur J Cancer; 2012 Nov; 48(17):3257-66. PubMed ID: 22770878
[TBL] [Abstract][Full Text] [Related]
7. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).
Maynadié M; Girodon F; Manivet-Janoray I; Mounier M; Mugneret F; Bailly F; Favre B; Caillot D; Petrella T; Flesch M; Carli PM
Haematologica; 2011 Jan; 96(1):55-61. PubMed ID: 20971817
[TBL] [Abstract][Full Text] [Related]
8. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
9. Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries.
Polednak AP
J Registry Manag; 2014; 41(2):77-84. PubMed ID: 25153013
[TBL] [Abstract][Full Text] [Related]
10. Outcome of patients with myelodysplastic syndromes in the Veterans Administration population.
Komrokji RS; Matacia-Murphy GM; Al Ali NH; Beg MS; Safa MM; Rollison DE; List AF
Leuk Res; 2010 Jan; 34(1):59-62. PubMed ID: 19368972
[TBL] [Abstract][Full Text] [Related]
11. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.
Zeidan AM; Wang R; Davidoff AJ; Ma S; Zhao Y; Gore SD; Gross CP; Ma X
Cancer; 2016 May; 122(10):1598-607. PubMed ID: 26970288
[TBL] [Abstract][Full Text] [Related]
12. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006.
De Roos AJ; Deeg HJ; Onstad L; Kopecky KJ; Bowles EJ; Yong M; Fryzek J; Davis S
Am J Hematol; 2010 Oct; 85(10):765-70. PubMed ID: 20815079
[TBL] [Abstract][Full Text] [Related]
13. Surveillance of US deaths related to myelodysplastic syndromes, and the need for linkages with central cancer registries.
Polednak AP
J Registry Manag; 2011; 38(4):183-9. PubMed ID: 23270091
[TBL] [Abstract][Full Text] [Related]
14. Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance.
Polednak AP
Cancer Epidemiol; 2013 Oct; 37(5):569-74. PubMed ID: 23773300
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Burden of the Myelodysplastic Syndromes.
Cogle CR
Curr Hematol Malig Rep; 2015 Sep; 10(3):272-81. PubMed ID: 26134527
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
17. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012.
Bonadies N; Feller A; Rovo A; Ruefer A; Blum S; Gerber B; Stuessi G; Benz R; Cantoni N; Holbro A; Schmidt A; Lehmann T; Wilk CM; Arndt V;
Cancer Epidemiol; 2017 Feb; 46():85-92. PubMed ID: 28056392
[TBL] [Abstract][Full Text] [Related]
18. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment.
Cogle CR; Iannacone MR; Yu D; Cole AL; Imanirad I; Yan L; Mackinnon JA; List AF; Rollison DE
Leuk Res; 2014 Jan; 38(1):71-5. PubMed ID: 24280283
[TBL] [Abstract][Full Text] [Related]
19. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers.
De Roos AJ; Deeg HJ; Davis S
Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848
[TBL] [Abstract][Full Text] [Related]
20. Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries.
Solans M; Sanvisens A; Ameijide A; Merino S; Rojas D; Alemán A; Banqueri E; Chico M; Marcos AI; de Castro V; Gil L; de Munain AL; Puigdemont M; Sánchez MJ; Perucha J; Ruiz-Armengol P; Chirlaque MD; Guevara M; Carulla M; Marcos-Gragera R
Sci Rep; 2022 Jan; 12(1):323. PubMed ID: 35013373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]